Baird downgraded Maravai Lifesciences (MRVI) to Neutral from Outperform with a price target of $3, down from $9, after the company announced ...

Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to ...

Law Offices of Howard G. Smith announces an investigation on behalf of Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ: MRVI) investors concerning the Company's possible ...

In a report released today, Matt Larew from William Blair maintained a Hold rating on Maravai Lifesciences Holdings (MRVI – Research Report).

Shares of Maravai LifeSciences (NASDAQ:MRVI) dipped over 15% premarket on Tuesday after the company said it is postponing its earnings release and call scheduled for today (Feb. 25, 2025). The life ...

Maravai LifeSciences Holdings (NASDAQ:MRVI) is scheduled to announce Q4 earnings results on Tuesday, February 25th, after market close. The consensus EPS Estimate is -$0.04 (+95.0% Y/Y) and the ...

On Tuesday, February 25, 2025, Maravai LifeSciences disclosed that it would be postponing its previously announced earnings release and call scheduled for February 25, 2025, and it would be unable to ...

NASDAQ:MRVI opened at $4.11 on Friday. Maravai LifeSciences has a one year low of $3.93 and a one year high of $11.56. The stock has a market cap of $1.04 billion, a P/E ratio of -2.51 and a beta ...

1 Day MRVI 4.05% DJIA -1.69% S&P Mid Cap 400 -2.40% Health Care/Life Sciences -0.37% ...